Piramal Pharma Solutions ('PPS'), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ('PPL') (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.&n
Piramal Pharma Solutions ('PPS'), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd.
('PPL') (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug...
PRNewswire Mumbai (Maharashtra) [India], October 1: Piramal Pharma Solutions ('PPS'), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Piramal Pharma Solutions ('PPS'), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ('PPL') (NSE: PPLPHARMA) (BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October.&n PRNewswire Mumbai (Maharashtra) [India], October 1:
PRNewswire Mumbai (Maharashtra) [India], October 1:
Open the app view to save this story, compare related coverage, and continue from the same source.